Neratinib Completed Phase 1 Trials for Neoplasms, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00146172Study Evaluating HKI-272 in Tumors